Gene therapy for hereditary deafness: Progress, challenges and translational implications from OTOF to GJB2
- 1Department of Otorhinolaryngology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan P. R. China
Abstract
Background Hereditary deafness is a common sensory disorder in infants and children. Gene therapy has achieved major clinical breakthroughs in OTOF‐related deafness, establishing proof of concept for treating monogenic hearing loss. In contrast, GJB2‐related hearing loss remains more challenging because of its broad cochlear expression, complex supporting‐cell targets, developmental involvement, and narrow therapeutic window. Methods We reviewed recent advances in hereditary deafness gene therapy, focusing on the translational progression from OTOF to GJB2. We summarize early inner‐ear gene‐therapy efforts, clinical and preclinical developments in OTOF‐targeted therapy, and current GJB2‐directed strategies, including gene replacement, cell‐specific delivery, base editing, pharmacological rescue, and potential in utero intervention. Results OTOF gene therapy has progressed to clinical trials, with dual‐adeno‐associated‐virus strategies producing substantial and durable hearing restoration in patients with DFNB9. Its success is supported by preserved cochlear architecture and efficient inner‐hair‐cell targeting. GJB2 therapy remains at the preclinical or early‐clinical stage. Major barriers include the broad distribution of connexin 26‐expressing cells, the need for precise supporting‐cell targeting, limitations of current disease models, developmental differences between mice and humans, and irreversible cochlear abnormalities before postnatal treatment. Conclusion OTOF provides an important translational framework, but GJB2 requires distinct strategies involving precise cochlear delivery, controlled transgene expression, improved models, large‐animal validation, and potentially earlier intervention.
Related
- A translational pipeline for classification of variants of uncertain significance to support gene therapy clinical trial in OTOF-related deafness
- Unravelling the Genetic Basis of Insect Resistance in Maize: Progress and Future Challenges
- Centrosomal protein 55: Research progress on biological characteristics, disease associations and clinical translational potential (Review)
- Genetically modified crops in Africa: progress, challenges, and future prospects.
- MSC-derived extracellular vesicles for spinal cord injury: inflammatory microenvironment modulation, stage-dependent repair mechanisms, and translational challenges
BibTeX
@article{zhao2026gene,
title = {{Gene therapy for hereditary deafness: Progress, challenges and translational implications from OTOF to GJB2}},
author = {Jiahui Zhao and Mengzhao Xun and Yu Sun},
journal = {Clinical and Translational Discovery},
year = {2026},
month = oct,
doi = {10.1002/ctd2.70203},
url = {https://doi.org/10.1002/ctd2.70203},
note = {CC BY},
}
RIS
TY - JOUR
TI - Gene therapy for hereditary deafness: Progress, challenges and translational implications from OTOF to GJB2
AU - Jiahui Zhao
AU - Mengzhao Xun
AU - Yu Sun
PY - 2026
DA - 2026/10/26
JO - Clinical and Translational Discovery
DO - 10.1002/ctd2.70203
UR - https://doi.org/10.1002/ctd2.70203
AB - Background Hereditary deafness is a common sensory disorder in infants and children. Gene therapy has achieved major clinical breakthroughs in OTOF‐related deafness, establishing proof of concept for treating monogenic hearing loss. In contrast, GJB2‐related hearing loss remains more challenging because of its broad cochlear expression, complex supporting‐cell targets, developmental involvement, and narrow therapeutic window. Methods We reviewed recent advances in hereditary deafness gene therapy, focusing on the translational progression from OTOF to GJB2. We summarize early inner‐ear gene‐therapy efforts, clinical and preclinical developments in OTOF‐targeted therapy, and current GJB2‐directed strategies, including gene replacement, cell‐specific delivery, base editing, pharmacological rescue, and potential in utero intervention. Results OTOF gene therapy has progressed to clinical trials, with dual‐adeno‐associated‐virus strategies producing substantial and durable hearing restoration in patients with DFNB9. Its success is supported by preserved cochlear architecture and efficient inner‐hair‐cell targeting. GJB2 therapy remains at the preclinical or early‐clinical stage. Major barriers include the broad distribution of connexin 26‐expressing cells, the need for precise supporting‐cell targeting, limitations of current disease models, developmental differences between mice and humans, and irreversible cochlear abnormalities before postnatal treatment. Conclusion OTOF provides an important translational framework, but GJB2 requires distinct strategies involving precise cochlear delivery, controlled transgene expression, improved models, large‐animal validation, and potentially earlier intervention.
SN - 2768-0622
ER -